61% of people with eyelid eczema in one study turned out to have a contact allergy. The top culprit wasn't even a face product. It was nail polish.

That's the catch with eczema on your face. The skin is thin and reactive, so the strong creams that calm an elbow can cause new trouble here. So how do you treat it, eyelids included, without making things worse?

Quick Answer: How do you treat eczema on your face?

Six ways calm facial eczema: gentle care, low-potency steroids, steroid-free creams, avoiding triggers, and maintenance. Facial skin is thin, so strong steroids carry extra risk there. Honeydew's providers usually lean on steroid-free prescriptions for the face and eyelids, saving mild steroids for short flares.

Here's what drives the rash, then six ways to treat it and keep flares away. For the rest of the body, see our full eczema guide.

What's causing the rash on your face?

A rash that looks like eczema on your face is usually one of three conditions, each treated a little differently. The first is atopic dermatitis, the chronic, itchy type most people mean when they say "eczema." In a 2025 analysis of 100 cases, facial atopic dermatitis showed up most often on the forehead (68%), cheeks (60%), and around the eyes (57%).

The second is contact dermatitis, a reaction to something touching your skin. It can be irritation from harsh products or a true allergy to one ingredient. In the eyelid study above, cosmetics caused most of the allergy cases. Your hands carry products to your face all day, so the trigger isn't always something you put there on purpose.

“Our immune systems are amazing and complicated,” says Elizabeth Cooper, Nurse Practitioner. “You can develop new contact allergies at any point in your lifetime.”

The third is seborrheic dermatitis, a lookalike that tends to appear on the eyebrows, beard, ears, and the skin around the nostrils. It usually has white-to-yellowish scale that can look greasy and needs a different treatment plan, one reason a stubborn facial rash deserves a proper diagnosis.

Webinar: Face the Facts: All About Facial Eczema (National Eczema Association).

Whichever type you have, the six ways below start with the daily routine that sets the ceiling for how well treatment works.

1. A gentle daily skin care routine

A gentle, steady routine is the base of every facial eczema plan, and the AAD's 2023 guidelines give moisturizers a strong recommendation. Dermatologists point to these habits most:

  • Wash gently: A mild, soap-free cleanser and lukewarm water clean without stripping. Pat dry instead of rubbing.
  • Moisturize right after: A fragrance-free cream or ointment on slightly damp skin helps hold water in.
  • Keep it fragrance-free: Fragrance is a common irritant for reactive skin, so shorter ingredient lists are easier on a flaring face.
  • Choose sunscreen carefully: For allergy-prone skin, the AAD suggests skipping sunscreens with fragrance, parabens, or oxybenzone, and using a sunscreen stick around the eyes so nothing drips in. “Go for mineral or baby sunscreen,” recommends Cooper.
  • Go product-light during a flare: New serums, exfoliating acids, and heavy makeup can wait until the skin settles. Add them back one at a time. “One at a time is important, this can help identify the potential trigger,” suggests Cooper.
  • Hands off: Scratching and rubbing break the skin and feed the itch.

Testing a new product on a small spot first can catch a reaction before it reaches your face. If the rash keeps flaring even with a careful routine, the next step is usually a medicated cream.

2. Short courses of low-potency steroid cream

Low-potency steroid creams are generally considered safe on the face for short courses, and the same AAD guidelines strongly recommend topical steroids for eczema. In a Cochrane review, skin thinning was rare across trials but grew more common as steroid strength went up.

That's why strength and timing matter on the face. Over-the-counter hydrocortisone 1% is a low-potency option. Its Drug Facts label says to keep it away from the eyes, use it no more than 3 to 4 times a day, and stop and ask a doctor if symptoms last over 7 days.

Overuse carries its own risk. Topical steroid withdrawal is red, burning, itchy skin that can follow long-term steroid use once it stops. A 2025 review found the face is the most affected area, and stronger steroids raise the risk. There are still no firm diagnostic criteria for it, so it's easy to mistake for a regular flare.

Elizabeth Cooper, DNP

“Steroid creams on the face are safe when used correctly. You want to use the lowest potency as possible for the shortest amount of time. Typically no longer than twice daily for two weeks max. Prolonged use on the face can eventually cause withdrawal, acne, perioral dermatitis, skin thinning, and can affect eye health when used on the eyelids.”

— Elizabeth Cooper, DNP | Nurse Practitioner

Red flag: If your face turns red, burns, or stings after you stop a steroid cream, talk to a provider before you restart it. That pattern can be steroid withdrawal rather than eczema.

That's a big reason dermatologists often turn to steroid-free creams for facial skin.

3. Steroid-free calcineurin inhibitors

Several prescription creams calm eczema without any steroid, and the 2023 AAD guidelines strongly recommend all three main types: calcineurin inhibitors, PDE-4 inhibitors, and JAK inhibitors. The longest-used are the topical calcineurin inhibitors, tacrolimus and pimecrolimus. A 2026 review describes them as a practical option for sensitive areas, including the face and eyelids.

Tacrolimus comes in two strengths. Its prescribing information limits 0.1% to adults and uses 0.03% for children ages 2 to 15. Our tacrolimus ointment page covers the details.

What to expect: Burning is the most common side effect, reported by 58% of adults on 0.1% in the label's trials, compared with 26% on a plain ointment. It's most common in the first few days and tends to ease as the skin heals. The label also warns that alcohol can make the treated face flush red and feel hot.

Elizabeth Cooper, DNP

“Some temporary burning at the start of using tacrolimus is normal, your skin is sensitive and inflamed and it should improve over the first few days. If the stinging lasts more than 5 minutes, let your provider know.”

— Elizabeth Cooper, DNP | Nurse Practitioner

4. Newer PDE-4 and JAK inhibitor creams

Newer steroid-free creams include two PDE-4 inhibitors, crisaborole and roflumilast, and a JAK inhibitor, ruxolitinib. Crisaborole ointment is approved from 3 months of age. Roflumilast cream 0.15% goes on once a day from age 6, and 42% of participants in its eczema trials had it on the face.

Ruxolitinib cream improved facial eczema more than a plain cream in a face and neck trial, though one key measure (37.0% vs 17.4% reaching 75% improvement) missed statistical significance. Its label carries a boxed warning and limits how much skin and cream you can use.

Here's how the main facial eczema creams compare on their labels:

TreatmentTypeHow it's used (label)Worth knowing for the face
Hydrocortisone 1% (OTC)Low-potency steroidUp to 3–4 times a dayKeep away from the eyes; see a doctor if symptoms last over 7 days
Tacrolimus ointmentCalcineurin inhibitorTwice a day; 0.1% for adults, 0.03% for ages 2–15Burning in 58% of adults on 0.1%, mostly in the first few days
Crisaborole ointmentPDE-4 inhibitorTwice a day; ages 3 months and upBurning or stinging at the application site in 4%
Roflumilast cream 0.15%PDE-4 inhibitorOnce a day; ages 6 and up (0.05% for ages 2–5)42% of trial participants had facial eczema
Ruxolitinib cream 1.5%JAK inhibitorTwice a day on up to 20% of the body; ages 2 and upBoxed warning; one 60 g tube a week maximum for ages 12 and up

Clearing a flare is half the job. Keeping it clear is the other half.

5. Finding and avoiding your triggers

Keeping flares away starts with finding what sets your skin off. Patch testing checks your skin against common allergens over a few days and is how allergic contact dermatitis gets confirmed.

In the eyelid study, 80.3% of people tested had at least one positive result. Once a trigger is named, avoiding it can do what no cream can.

Elizabeth Cooper, DNP

“Most common triggers I see for recurring facial rashes are fragrances, preservatives, metals (i.e. nickel), gel nails, and too many exfoliants. Contact allergy patch testing can help identify your specific allergy to avoid if we can’t nail down an obvious cause.”

— Elizabeth Cooper, DNP | Nurse Practitioner

6. Twice-weekly maintenance therapy

Once a flare clears, what you do next shapes how soon the next one arrives. In the same Cochrane review, twice-weekly "weekend" steroid use, also called proactive therapy, cut relapse from 58% to 25% across 7 trials, compared with no maintenance or as-needed use.

That research covered eczema in general, so ask your provider about a plan for your face. Some signs mean home care and a maintenance plan aren't enough.

When should you see a provider for eczema on your face?

See a provider if facial eczema isn't improving, keeps coming back, or sits on your eyelids, where the skin is delicate. Labels set timelines too: the tacrolimus label calls for a re-check if symptoms don't improve within 6 weeks.

For adults with widespread, moderate-to-severe eczema that creams can't control, the AAD's systemic guidelines strongly recommend biologic injections such as dupilumab and tralokinumab, or JAK inhibitor pills.

Red flag: Get care promptly if facial eczema oozes, crusts over, becomes painful or swollen, spreads quickly, or comes with fever, eye pain, or vision changes. These can signal an infection or an eye problem that needs treatment right away.

Facial eczema is easy to see, which makes it well suited to photo-based care. Through our online eczema care, you fill out a medical questionnaire and upload photos. In many cases, treatment can start without a video visit. Honeydew is trusted by 30,000+ patients, according to the count on our site.

Honeydew Recommends

Honeydew's providers recommend treating most eczema on the face with a gentle, fragrance-free routine and a steroid-free prescription as the everyday anti-inflammatory, keeping a low-potency steroid for short flare courses. Steroid-free creams suit thin facial and eyelid skin, and the face is where steroid withdrawal shows up most, so this split calms flares while keeping steroid exposure low.

If your eyelids are involved or the rash keeps returning, our providers look for a product allergy or a lookalike such as seborrheic dermatitis before stepping up treatment. Widespread moderate-to-severe eczema may call for a biologic or JAK inhibitor instead. “Some insurance plans may also want to see failure of step therapy before approving advanced therapies,” says Cooper.

There are honest limits: tacrolimus often stings for the first few days, some newer creams may need prior authorization from your insurer, and no cream can outwork an allergen you're still touching.

At the end of the day, managing facial eczema comes down to personalized care and patience. When you partner with a provider who understands the nuances of delicate skin, you don’t have to cycle through trial-and-error alone. Together with your provider, you can pinpoint the root cause, navigate insurance hurdles, and build a sustainable routine that protects your skin barrier for the long haul.

Your first consultation is free, and Honeydew membership starts at $25/month with an annual plan. Medications aren't included in the membership. They're prescribed to outside pharmacies and may be covered by insurance, and we help with prior authorizations. For some generics, the cash price can be lower than an insurance copay. The membership is HSA/FSA eligible.

If the eczema on your face isn't settling, start your free online consultation and get a plan built for your skin.

References Cited

  1. American Academy of Dermatology. (2024, April 25). How do I know if I'm using the right sunscreen? aad.org
  2. Arcutis Biotherapeutics, Inc. (2026, July). ZORYVE (roflumilast) cream [Package insert]. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  3. Chiesa Fuxench, Z. C., Lai, Z., Kuo, Y., Nawaz, H., & Cotliar, J. (2025). Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: Results from a decentralized, randomized phase 2 clinical trial. Journal of Dermatological Treatment, 36(1), Article 2480744. doi.org
  4. Davis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., Silverberg, J. I., Singh, A. M., Wu, P. A., & Sidbury, R. (2024). Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 90(2), e43–e56. doi.org
  5. de Figueiredo Silva Hafner, M., Cerqueira Elia, V., Lazzarini, R., & Duarte, I. (2023). Demographic and clinical characteristics of patients with eyelid eczema attended at a referral service from 2004 to 2018. Anais Brasileiros de Dermatologia, 98(1), 84–86. doi.org
  6. Encube Ethicals, Inc. (2025, October). Tacrolimus ointment 0.1% (tacrolimus) [Package insert]. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  7. Incyte Corporation. (2026, June). OPZELURA (ruxolitinib) cream [Package insert]. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  8. Kenvue Brands LLC. (2026, January). AVEENO 1% Hydrocortisone Anti-Itch Cream (hydrocortisone) [Package insert]. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  9. Kim, T.-E., Ahn, H.-J., & Shin, M. K. (2025). Proposal of phenotypic patterns in facial atopic dermatitis: A single-center retrospective analysis of 100 cases. Annals of Dermatology, 37(6), 377–382. doi.org
  10. Kumar, R., Rabbani, S. A., El-Tanani, M., Sharma, S., & Saini, M. (2026). Calcineurin inhibitors in atopic dermatitis: Balancing tradition with emerging therapeutics. Medical Sciences, 14(2), Article 297. doi.org
  11. Lax, S. J., Harvey, J., Axon, E., Howells, L., Santer, M., Ridd, M. J., Lawton, S., Langan, S., Roberts, A., Ahmed, A., Muller, I., Ming, L. C., Panda, S., Chernyshov, P., Carter, B., Williams, H. C., Thomas, K. S., & Chalmers, J. R. (2022). Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database of Systematic Reviews, (3), Article CD013356. doi.org
  12. Ludmann, P. (2022, December 6). Seborrheic dermatitis: Overview. American Academy of Dermatology. aad.org
  13. Maskey, A. R., Sasaki, A., Sargen, M., Kennedy, M., Tiwari, R. K., Geliebter, J., Safai, B., & Li, X.-M. (2025). Breaking the cycle: A comprehensive exploration of topical steroid addiction and withdrawal. Frontiers in Allergy, 6, Article 1547923. doi.org
  14. Pfizer Laboratories Div Pfizer Inc. (2025, September). EUCRISA (crisaborole) ointment [Package insert]. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  15. Sidbury, R., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Drucker, A. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., Silverberg, J. I., Singh, A. M., Wu, P. A., & Davis, D. M. R. (2023). Guidelines of care for the management of atopic dermatitis in adults with topical therapies. Journal of the American Academy of Dermatology, 89(1), e1–e20. doi.org